Skip to main content

Leadership

2011 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
12/28/11Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia Printer Friendly Version
12/28/11Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott Printer Friendly Version
12/21/11Emergent BioSolutions Announces Fuad El-Hibri to Retire as CEO, Remain as Executive Chairman of the Board of Directors Focused on Corporate Strategy and M&A Opportunities Printer Friendly Version
12/12/11Emergent BioSolutions to Participate in January 2012 Investor Conferences Printer Friendly Version
12/05/11Emergent BioSolutions Announces Acceptance of Four TRU-016 Abstracts for Presentation at 2011 American Society of Hematology Annual Meeting Printer Friendly Version
12/01/11Emergent BioSolutions Receives Orphan Drug Designation for Its TRU-016 Protein Therapeutic for the Treatment of Chronic Lymphocytic Leukemia Printer Friendly Version
11/17/11Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis Printer Friendly Version
11/03/11Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2011 Printer Friendly Version
11/02/11Emergent BioSolutions to Participate in November 2011 Investor Conferences Printer Friendly Version
10/20/11Emergent BioSolutions to Release Third Quarter 2011 Financial Results and Conduct a Conference Call on November 3, 2011 Printer Friendly Version
10/03/11Emergent BioSolutions Receives Award to Supply 44.75 Million Doses of BioThrax to U.S. Government over Five Years Printer Friendly Version
09/14/11Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference in London Printer Friendly Version
09/09/11Emergent BioSolutions Co-Hosts Biopreparedness Conference with the French High Committee for Civil Defense Printer Friendly Version
08/26/11Results of Emergent BioSolutions Phase 1a Study on Adjuvanted BioThrax Anthrax Vaccine Published in the Journal Vaccine Printer Friendly Version
08/17/11Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed - Indolent Lymphoma Printer Friendly Version
08/11/11New Tuberculosis Vaccine Enters Phase IIb Proof-of-Concept Trial in People Living with HIV in Senegal and South Africa Printer Friendly Version
08/09/11Emergent BioSolutions to Present at Wedbush 2011 Life Sciences Conference Printer Friendly Version
08/04/11Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2011Download PDFPrinter Friendly Version
07/11/11Emergent BioSolutions to Release Second Quarter 2011 Financial Results and Conduct a Conference Call on August 4, 2011Download PDFPrinter Friendly Version
06/23/11Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax Printer Friendly Version
06/13/11Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors Printer Friendly Version
06/09/11Emergent BioSolutions' Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation Printer Friendly Version
06/06/11Emergent BioSolutions Acquires Late-Stage Monoclonal Antibody Cancer Therapy from TenX BioPharma Printer Friendly Version
05/31/11Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule Printer Friendly Version
05/26/11U.S. Government Issues Request for Proposal for the Supply of 44.75 Million Doses of BioThrax over Next 5 Years Printer Friendly Version
05/25/11Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference Printer Friendly Version
05/17/11Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2011 at 10:00 am Eastern; Webcast Will Be Available Printer Friendly Version
05/05/11Emergent BioSolutions Reports Financial Results for First Quarter 2011 Printer Friendly Version
05/02/11U.S. Government Expands BioThrax Procurement Contract to 17.92M Doses from 14.5M Increasing Contract Value by up to $101 Million Printer Friendly Version
04/28/11Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in Phase IIb Clinical Trial Printer Friendly Version
04/14/11Emergent BioSolutions to Release First Quarter 2011 Financial Results and Conduct a Conference Call on May 5, 2011 Printer Friendly Version
04/12/11Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress Printer Friendly Version
03/24/11Emergent BioSolutions Observes World TB Day Printer Friendly Version
03/22/11Emergent BioSolutions to Present at Needham & Company Healthcare Conference Printer Friendly Version
03/10/11Emergent BioSolutions Reports Financial Results for Full Year 2010 Printer Friendly Version
02/25/11Delegates from European Parliament Express Support for Rapid Development of New TB Vaccine Printer Friendly Version
02/24/11Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10, 2011 Printer Friendly Version
01/25/11Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocytic Leukemia Printer Friendly Version
01/10/11Emergent BioSolutions Provides Preliminary 2010 Financial Results and Guidance for 2011 Printer Friendly Version